Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
| PINNACLE FINANCIAL PARTNERS INCPNFP · Entity 70624 | Director | March 01, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,656 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 63,656 |
PINNACLE FINANCIAL PARTNERS INC
Report date March 01, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PNFP Common StockSEC Table I · non-derivative | Direct | 24,168 |
Ending reported balance
After 2024-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-01 · Tax withholding · Disposed 239 · Balance 23,179 F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards. Row 2 · 2024-03-01 · Grant · Acquired 989 · Balance 24,168 F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves. |
| Depositary SharesSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2024-03-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,000 F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to cover taxes due upon the vesting of certain restricted share awards.
F2: Represents shares with restrictions that lapse on March 1, 2025 based on attendance at Pinnacle Board and Committee meetings to which the above-named director serves.
F3: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.22 | $241.50 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,492 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| September 04, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.29 | $246.75 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,417 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| September 03, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.35 | $251.25 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,342 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| September 02, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.32 | $249.00 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,267 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| September 01, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.24 | $243.00 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,192 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| August 31, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.25 | $243.75 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,117 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| August 28, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.24 | $243.00 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,042 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| August 27, 2020 Filed Feb 5, 2021 22:49 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 75 | $3.28 | $246.00 |
DisclosureSEC source: 0001209191-21-008229 · doc5.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,967 F1 · shares: The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. F2 · shares: Filing 1 of 3 Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 225 | $3.29 | $740.25 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,892 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| August 21, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.35 | $1,256.25 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,667 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| August 14, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.44 | $1,290.00 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,292 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| August 07, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.42 | $1,282.50 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,917 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| July 31, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.26 | $1,222.50 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,542 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| July 24, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.33 | $1,248.75 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,167 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| July 17, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.29 | $1,233.75 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,792 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| July 10, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.31 | $1,241.25 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,417 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| July 02, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 300 | $3.34 | $1,002.00 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,042 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 26, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.37 | $1,263.75 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,742 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 19, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 375 | $3.41 | $1,278.75 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,367 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 12, 2020 Filed Aug 28, 2020 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 225 | $3.37 | $758.25 |
DisclosureSEC source: 0001209191-20-048659 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,992 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.48 | $261.00 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 30 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,767 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 08, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.54 | $265.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 29 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,692 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 05, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.44 | $258.00 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 28 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,617 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 04, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.31 | $248.25 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 27 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,542 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 09:05 UTC | PINNACLE FINANCIAL PARTNERS INC PNFP · Entity 70624 | PurchaseDepositary Shares | 4,000 | $25.00 | $100,000.00 |
DisclosureSEC source: 0001567619-20-011755 · doc1.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · security: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering. F1 · kind: Each depositary share represents a 1/40th interest in a share of the Issuer's 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share. Depositary shares purchased in an underwritten public offering. Read SEC document |
| June 03, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.29 | $246.75 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 26 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,467 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 02, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.35 | $251.25 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 25 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,392 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.45 | $258.75 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 24 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,317 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 29, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.35 | $251.25 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 23 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,242 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 28, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.34 | $250.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 22 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,167 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 27, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.49 | $261.75 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 21 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,092 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 26, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.59 | $269.25 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 20 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,017 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 22, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.61 | $270.75 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 19 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,942 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 21, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.68 | $276.00 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 18 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,867 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 20, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.77 | $282.75 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 17 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,792 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 19, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.78 | $283.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 16 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,717 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 18, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.82 | $286.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 15 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,642 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 15, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.76 | $282.00 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 14 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,567 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 14, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 75 | $3.81 | $285.75 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,492 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 13, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $3.93 | $589.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,417 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 11, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.02 | $603.00 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,267 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 07, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $3.97 | $595.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,117 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 05, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $3.99 | $598.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,967 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| May 01, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.01 | $601.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,817 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| April 29, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.01 | $601.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,667 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| April 27, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.02 | $603.00 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,517 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| April 23, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.03 | $604.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,367 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| April 21, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.03 | $604.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,217 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| April 17, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.04 | $606.00 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,067 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
| April 15, 2020 Filed Jun 12, 2020 21:32 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 150 | $4.05 | $607.50 |
DisclosureSEC source: 0001209191-20-036360 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,917 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.